KRAS and Marinesco-Sjogren syndrome: Of note, 29 out of 235 patients with MSS tumors (12.3%) had a durable response to ICIs as measured by a TTD greater than 6 months, while 16 out of the 122 patients with MSS/KRAS-mutated tumors (13.1%) had a durable response to ICIs.